Armed Chimeric VSV Viruses for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic VSV-based cancer therapies face challenges with inconsistent immune responses and sub-optimal cytolytic profiles, necessitating improved recombinant viruses with enhanced safety and efficacy for cancer treatment.
Innovation Solution
Development of armed, chimeric Vesicular Stomatitis Viruses (VSV) incorporating heterologous viral glycoproteins from Arenaviridae, Filovirus, Togovirus, and Paramyxoviridae families, along with immunomodulatory molecules like IL-12 and CD40L, to enhance immune response and cytolytic activity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oncolytic VSV-based cancer therapies are used, then cancer treatment is provided, but immune responses are inconsistent and cytolytic profiles are sub-optimal
Solution Approach 1:
The patent combines multiple functional elements into a single oncolytic virus platform: VSV backbone for oncolysis, heterologous glycoproteins for expanded tropism and immune stimulation, and immunomodulatory molecules (IL-12, CD40L) for enhanced immune response. This merging of functions resolves the contradiction by creating a multi-functional virus that simultaneously achieves consistent immune responses and optimal cytolytic activity.
Solution Approach 2:
The invention creates a composite viral structure by integrating foreign genetic elements (heterologous glycoprotein genes and immunomodulatory molecule genes) into the VSV genome. This composite approach allows the virus to exhibit properties of multiple components: the oncolytic capability of VSV, the expanded cell tropism of heterologous glycoproteins, and the immune-enhancing effects of cytokines like IL-12 and CD40L.
2Object-affected harmful factors
If VSV is used as an oncolytic virus, then cancer cells are targeted, but safety and efficacy need enhancement
Solution Approach 1:
The patent applies local quality by selectively enhancing specific properties of the VSV at different locations: the glycoprotein portion is modified to expand tropism and enhance immune recognition, while the internal viral components maintain their oncolytic function. Immunomodulatory molecules are locally expressed at the infection site to enhance anti-tumor immunity without affecting healthy tissues systemically.
Solution Approach 2:
The invention changes key parameters of the VSV to improve safety and efficacy: replacing or supplementing the native G protein with heterologous glycoproteins to alter cell tropism and immune evasion properties, and introducing immunomodulatory molecules to modify the immune response profile. These parameter changes enhance the virus's ability to selectively target and eliminate cancer cells while improving safety.
Data Source
AI summary
The present invention relates generally to the field of cancer therapy and oncolytic viruses. More particularly, it concerns armed, chimeric oncolytic viruses.